Market Overview

Sellas Reviews Strategic Options To Fund Clinical Development Programs

Share:
Sellas Reviews Strategic Options To Fund Clinical Development Programs

Cancer immunotherapy company Sellas Life Sciences Group Inc (NASDAQ: SLS) announced Tuesday that its board is conducting a review of strategic options in a bid to maximize shareholder value.

What Happened

Sellas said the strategic options it is weighing include a sale; business combination; merger or reverse merger with another company; strategic investment/financing; or a funded collaboration or partnership that will allow it to advance the development of its lead product candidates galinpepimut-S, or GPS, and nelipepimut-S, or NPS.

The company said it has roped in Cantor Fitzgerald to assist in the review process.

Why It's Important

Sellas is planning a Phase 3 registrational study for GPS monotherapy in treating acute myeloid leukemia, or AML. The FDA has already reviewed the late-stage study protocol.

Sellas also initiated a Phase 1/2 prospective multi-arm, open-label, multi-institutional U.S.-only clinical study of GPS in combination with Merck & Co., Inc. (NYSE: MRK)'s Keytruda for multiple cancers, including AML; ovarian cancer; triple-negative breast cancer, or TNBC; small cell lung cancer, or SCLC; and colorectal cancer.

Sellas' other lead asset NPS is being developed for TNBC, and the company is in discussions with the FDA regarding the design of a Phase 3 registrational trial.

At the time of the release of its third-quarter results, Sellas said it had unrestricted cash and cash equivalents totaling $10  million, not including a $6.6-million payment related to the settlement of litigation with JGB in November 2018.

Sellas shares were up 3.52 percent at $1.47 at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Posted-In: Cantor FitzgeraldBiotech News Trading Ideas General Best of Benzinga

 

Related Articles (MRK + SLS)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

FreightWaves Secures $20 Million In Series B Funding From Corporate And Strategic Investors

'They've Got To Diversify': Anheuser-Busch Buys Liquor, Canned Cocktail Company Cutwater